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Myocardial fibrosis is one of the main structural changes following cardiomyocyte injury such as infarction. Macrophages play a 
central role in the development offibrotic lesions. In myocardial fibrosis, three different populations of macrophages are 
recognized: exudate macrophages, resident macrophages, and interstitial dendritic cells. Exudate macrophages, which are 
derived from blood monocytes and recruited into injured areas through chemoattractants and cell adhesion molecules, release 
various fibrogenic growth factors in early stages of the fibrosis. Transforming growth factor- f! and platelet-derived growth 
factors are proposed as the most probable growth factors produced by exudate macrophages to induce the modulation of 
fibroblasts towards myofibroblasts. Emerging evidence shows that macrophage-secreted nerve growth factor may also be 
involved in that process. The myofibroblasts are capable of producing extracellular matrix proteins which contribute to myocardial 
fibrosis. The exudate macrophages also participate in the induction ofapoptosis in injured myocytes and myofibroblasts in the 
fibrotic lesions. These apoptotic cells are phagocytized by exudate macrophages, and the macrophages themselves also disappear 
by apoptosis. The decrease in cellularity by apoptosis leads to the evolution of fibrous granulation tissues into scar tissues 
(reparative fibrosis). The resident macrophages particiapte exclusively in the late stages of the myocardial fibrosis, when their mitotic 
activity increases in the lesions; they are presumed to have the same roles as the exudate macrophages. In addition, the resident 
macrophages and interstitial dendritic cells both act as immune mediators to recruit T-lymphocytes into the lesions. In contrast to 
hepatic, pulmonary, and renal fibrosis, the roles of macrophage populations in myocardial fibrosis has not yet been extensively 
investigated. BiomedRev 1999; 10:89-105. 
 
INTRODUCTION 
Fibrosis is a common sequel following diverse insults in a 
variety of parenchymal tissues. The change is a part of the tissue 
repair process and contributes to the tissue remodeling (1-3). 
However, if it occurs progressively or repeatedly in major 
organs such as liver, lungs, kidneys, and heart, it results in 
serious functional insufficiency in these organs, leading in some 
cases to death. The fibrosis is evoked through complicated 
processes after tissue injuries (4,5), and the mechanisms have 
yet to be fully characterized. In the last decade, there have been 
significant advances in cellular and molecular pathology, which 
have contributed to our understanding of the roles of cells and 
factors responsible for the development of fibrosis. These 
advances have shown that macrophages (M0) play a pivotal 
role in fibrogenesis and consequent tissue remodeling (6-9). 
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Our laboratory has been investigating the kinetics of M0 and 
fibrogenic cells in rat fibrosis models, in order to shed some light on 
the roles of M0 in the development of fibrosis. These models 
include hepatic (10,11), renal (12-15) and cardiac (16) fibrosis. In 
this review article, general mechanisms of fibrosis will be 
discussed, together with the current notion on the derivation and 
differentiation of M0 populations. Then, we will highlight recent 
insights on the roles of M0 in myocardial fibrosis by referring 
to those in fibrotic lesions in the liver, lungs and kidneys as 
well as skin wound healing. With this knowledge, the possible 
therapeutic strategies to limit progression of fibrosis are briefly 
introduced. 
THE PATHOLOGY OF FIBROSIS 
Animal models 
Many fibrosis models have been established in rats and mice 
by various experimental strategies. These models have 
contributed significantly to the elucidation of cellular and 
molecular mechanisms responsible for the fibrogenesis (Table 
1). 
The fibrogenic processes 
The development of fibrosis requires the participation of various 
soluble factors capable of mediating cell-cell and cell-
extracellular matrix (ECM) interactions, inflammatory responses, 
and abnormal accumulation of ECM proteins (2,4,5). Based on 
results obtained in fibrosis models, several common and general 
features have been ascertained at present, although the 
fibrogenic processes certainly vary from model to model and 
from organ to organ. The fibrogenic processes consist generally 
Table 1. Experimental fibrosis models in rats and mice 
of three phases (Table 2). The firstphase represents the induction of 
conditions necessary for the establishment of active fibrosis and 
the functional elaboration of reactive cells including M0. The 
second phase is composed of the development of fibrogenic cells 
and subsequent deposition of ECM proteins. The third phase 
provides the resolution towards healing and tissue 
remodeling. However, one should notice that each phase is 
sequential, and that the fibrotic lesions will become more 
complicated depending on the degree and extent of injured 
tissues as well as the underlying causes. 
The firstphase of fibrogenic process 
In this phase, the recruitment of inflammatory cells from blood or 
surrounding tissues is a prerequisite for the development of 
fibrosis. In response-to-injury, vascular endothelial cells, pa-
renchymal and/or inflammatory cells produce factors to attract 
and activate M0, neutrophils, lymphocytes, and mast cells, 
using para- and autocrine pathways. There are several classes of 
chemoattractants/chemokines and cell adhesion molecules 
(CAM) (7,17-22). CAM such as vascular cell adhesion 
molecule-1 (VCAM-1), intercellular adhesion molecule-1 
(ICAM-1), lymphocyte function-associated antigen-1 (LFA-
1), (32-integrin-macrophage-1 antigen (Mac-1), very late 
antigen-4 (VLA-4), and osteopontin are important factors for 
the adhesion of blood monocytes to vascular endothelial cells 
at inflammatory sites (17,20,22,23). In this migration 
process, chemoattractants such as monocyte chemoattractant 
protein-1 (MCP-1), macrophage-colony stimulating factor (M-
CSF), granulocyte-macrophage colony stimulating factor (GM-
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factors-beta (TGF-p) are capable of inducing monocyte 
chemotaxis (7,21,23-27). In particular, MCP-1 has a high 
potential for monocytes, stimulating their infiltration into 
inflammatory sites (7,21,22,28). During the first stage, 
recruited M0 release a number of cell growth factors such as 
TGF-p, platelet-derived growth factor (PDGF), TNF-oc, basic 
fibroblast growth factor (bFGF), and colony stimulating 
factors (CSF) (7,24,25,29-39). Among these factors, TGF-P 
and PDGF strongly modulate fibroblast phenotype and ECM 
product ion both in vitro and in vivo (7,29,30,31,33, 
36,37,39,40,41), and endothelin (42) also induce activation 
of fibrogenic cells. It is worth mentioning that most of the 
immune/inflammatory cells including human M0 (43,44) are 
source of and target for nerve growth factor (NGF). These 
findings suggest that NGF, in addition to its neurotrophic 
function, is an important para- and autocrine 
immunoregulatory factor, and hence implicated in a variety of 
pathological processes in inflammatory-fibroproliferative 
diseases, such as systemic sclerosis, skin wounds, and 
atherosclerosis (see this volume of Biomedical Reviews). In 
addition, recent evidence shows that the upregulation of 
cardiomyocyte myostatin, a member of the superfamily of 
TGF-P, after myocardial infarction could play an important 
role in cardiac pathophysiol-ogy (44a). 
The second phase of fibrogenic process 
In the second phase, M0-secreted growth factors give rise to 
the phenotypical conversion of fibroblasts into myofibroblasts. 
Myofibroblast development (fibrosing tissue) 
Phenotypical modulation of myofibroblasts 
(expression of vimentin, desmin, and/or a-smooth muscle actin) 
Extracellular matrix protein deposition 
  
Phase 3 
Resolution of fibrotic lesion 
Matrix metalloproteinases: collagenases, gelatinases, stromelysins, macrophage-metalloelastase, matrilysin 
Tissue inhibitors of metalloproteinases-1-4 
Apoptosis mediated by macrophge-produced factors 
Phagocytosis of apoptotic cells by macrophages 
 
 
Biomed Rev 10, 1999 
91 
Table 2. Pathology of fibrosis 
Phase 1 
Recruitment of inflammatory cells including exudate macrophages 
Cell-adhesion molecules Vascular cell adhesion molecule-1 
Intercellular adhesion molecule-1 
Lymphocyte function-associated antigen 
Macrophage-1 antigen Very late antigen-4 
Osteopontin 
Chemoattractants Monocyte-chemoattractant protein-1 
Macrophage-colony stimulating faictor (M-CSF) Granulocyte-
macrophge colony stimulating factor (GM-CSF) Tumor necrosis 
factor-a (TNF-a) Transforming growth factor-P (TGF-P) 
Production of fibrogenic growth factors by recruited/resident macrophages 
TGF-pl-3 
Platelet-derived growth factor (PDGF-AA, -BB) 
Basic fibroblast growth factor TNF-a M-CSF, GM-
CSF 
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In hepatic fibrosis, perisinusoidal cells (Ito cells, fat-storing 
cells or hepatic stellate cells) can modulate into 
myofibroblastic cells (10,45,46). The myofibroblasts are 
intermediate in nature between fibroblasts and smooth muscle 
cells (SMC), and thus are identified immunocytochemically 
by detection of SMC alpha-actin (oc-SMA) (4,33,38-41,42,47-
51). Through the secretion of inflammatory and antiinflam-
matory cytokines, chemokines, and growth factors, as well as 
ECM proteins and proteases, myofibroblasts play an important 
role in organogenesis, inflammation, repair, and fibrosis in 
most organs and tissues (reviewed in 52). In fibrotic lesions, it is 
known that cytoskeletal features change in the development of 
myofibro-blasts from stromal fibroblasts (47,50,52-54). The 
myofibroblast spectrum is divided into the following four main 
phenotypes: expressing of vimentin (V cells), coexpressing 
vimentin and desmin (VD cells), coexpressing vimentin and 
oc-SMA (VA cells), and coexpressing vimentin, a-SMA, and 
desmin (VAD cells). Such phenotypic modulations have been 
well established in fibroblastic cells appearing in skin wound 
healing, hypertrophic scar, superficial fibroma-tosis, and 
sclerodermal (47) and neoplastic (55) lesions. The major 
components of abnormally accumulated ECM proteins in 
fibrotic areas consist of collagen type I and type III, basal 
lamina-associated collagen type IV, laminin, and fibronectin 
(5,56). The phenotypically-modulated myofibroblasts produce 
mainly collagen types I and III, and fibronectin (56). Besides 
the production by myofibroblasts, basal lamina-related proteins 
may be produced by injured or regenerating parenchymal cells, 
for example, tubular epithelial cells in renal interstitial fibrosis 
and hepatocytes in liver fibrosis (4,5). Reactive cells in 
fibrotic lesions may express the major histocompatibility 
(MHC) class II molecules on cell surface, providing a 
mechanism for the direct involvement of antigen presentation 
to T-lymphocytes with subsequent production of cytokines 
that modulate the production of matrix proteins (4,57-59). 
The third phase offibrogenic process 
The third phase represents the resolution of fibrotic lesions, or 
further deposition of ECM proteins may occur. The abnormal 
accumulation of matrix proteins can be stimulated by altered 
balance between matrix metalloproteinases (MMP) including 
interstitial collagenase (MMP-1), gelatinase (MMP-2), stro-
melysin (MMP-3), M0-metalloelastase, and matrilysin and the 
tissue inhibitors of MMP (TIMP-1-4) (7,60-62). M0-secreted 
factors including NGF may influence the synthesis and activity 
of MMP (62-64). Another important event for the resolution of 
fibrotic lesions is the disappearance of cells that end their 
roles. The mechanism is due likely to apoptosis (2,9). 
MACROPHAGES 
Macrophage populations and their derivation 
M0 have been known to be present in fibrotic areas for a long 
time, indicating important roles for them in the fibrogenesis 
(4,5,7,8). In the 1970's, a theory of the "mononuclear phagocyte 
system (MPS)" was proposed (reviewed in 65). According to 
this theory, all M0, including infiltrating M0 in inflammatory 
lesions, and fixed M0 (so-called histiocytes) existing in various 
tissues, are derived from blood monocytes, which differentiate 
via promonocytes/monoblasts originating from bone marrow 
stem cells. These M0 were considered to be short-lived, 
nondividing terminal cells, although M0 in proliferative or 
regenerative lesions possess a proliferative capacity (66,67). 
Recently, it has been shown that M0 are not homogeneous cell 
populations. They differ in morphology, immunophenotypes, 
and functions (67-69). In adult life, three major M0 populations 
can be recognized: exudate M0, resident (fixed) M0, and 
dendritic cells (defined here as M0-related cells) (65,68,70). 
The development, differentiation, and maturation of these M0 
are shown in Figure 1. 
Exudate and resident macrophages 
Peroxidase (PO) is one of the most important enzymes involved in 
M0 functions (70,71), and differences in cytochemical localization 
patterns of PO activity between exudate and resident M0 
(65,70) have been noted. The exudate M0 show PO activity only 
in lysosomes. Analogous activity patterns are seen in blood 
monocytes. Therefore, the exudate M0 have been considered to 
be included in the monocytic lineage [macrophage-colony 
forming unit (M-CFU), monoblasts, promonoblasts and 
monocytes] originating from hematopoietic stem cells. In contrast, 
the resident M0 reveal PO activity patterns in the nuclear 
envelope and rough endoplasmic reticulum, and lack PO-posi-tive 
lysosomes. The resident M0 may also derived from 
hematopoietic stem cells including the M0 precursors (granulo-
cyte/macrophage-colony forming unit, GM-CFU) (65,67). 
However, they develop from PO-negative immature M0 through 
a differentiation pathway different from that of exudate M0. 
Ontogenetically, the M0 precursors migrate from the bone. 
marrow into connective tissues, then fix as PO-negative immature 
M0, and differentiate into resident M0 under conditions of 
inflammation. Monocyte-derived exudate M0 no longer have 
proliferative potential and are short-lived, whereas the resident 
M0 are long-lived in inactive steady state conditions in tissues, 
and can be sustained by self-renewal (65). In fact, Kupffer cells, 
a representative resident M0, show proliferative activity in 
diseased livers (45,46,66). 
According to cytoplasmic PO activity patterns, the exudate-
resident M0 population was distinguished. These cells show 
PO activity in the nuclear envelope, rough endoplasmic reticulum as 
well as lysosomes (70). Although the immunocytochemical 
studies indicated that the exudate-resident M0 constitute a 
subtype of blood monocytic exudate M0 (28,65), it is likely that 
they are a transitional or intermediate form between the exudate 
andresidentM0(67,70). As shown in Figure 1, the PO activity 
disappears in both exudate and resident M0 in the achieved 
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Figure 1. The development, differentiation and maturation of macrophage populations. The exudate macrophages are included in the 
monocytic lineage [macrophage colony forming unit (M-CFU), monoblasts, promonoblasts and monocytes] originating from 
hematopoietic stem cells. The resident macrophages are derived from hematopoietic stem cells including macrophage precursors 
(granulocyte/macrophage colony forming unit, GM-CFU); they develop from immature macrophages through differentiation 
pathway different from, that of the exudate macrophages; the immature macrophages migrate from the bone marrow, and then 
fix in the connective tissues. The exudate and resident macrophages are fundamentally distinguishable according to differences 
in cytochemical localization patterns ofperoxidase (PO) activity in the cytoplasm (see Text). However, there is a transitional or 
intermediate form somewhere between the exudate and resident macrophages. The PO activity disappears in both exudate and 
resident macrophages in the advanced stages of fibrosis. The interstitial dendritic cells develop from the hematopoietic stem cells 
including GM-CFU, and the precursor cells spread over the connective tissues. The differentiation pathway of the interstitial 
dendritic cells is distinct from that of the exudate or resident macrophages. However, some types of the interstitial dendritic cells 
may be formed from blood monocytes, and the relationship between the resident macrophages and interstitial dendritic cells in 
the fibrotic lesion remains unclear. The interstitial dendritic cells originally develop from MHC class II-negative precursors, and 
then give rise to low MHC class II-positive immature cells. Finally, the mature type of the interstitial dendritic cells upregulate 
the expression of MHC class II molecules in thefibrosing tissue. 
  
Dendritic cells 
Dendritic cells develop from the hematopoietic stem cells 
including GM-CFU, and the precursor cells at the immature 
situation spread overthe tissues (58,59,65,72).The differentiation 
pathway of dendritic cells is distinct from that of the exudate or 
resident M0 (65) (Fig. 1). However, it is considered that some 
types of dendritic cells are formed from blood monocytes (73). 
The dendritic cells include interstitial dendritic cells and 
interdigitatingfollicular cells of afferent lymphoid tissues such as 
the spleen, lymph nodes and Peyer's patches, and Langerhans cells 
of the epidermis. The interstitial dendritic cells are widely 
distributed in the connective tissues of most nonlymphoid 
organs, including the heart (58,59,73). Morphologically, the 
exudate and resident M0 have spherical lysosomal structures, 
while the interstitial dendritic cells are characterized by the 
presence of tubulovesicular systems consisting of numerous 
vesicles, sacs, and tubules (65,73). Dendritic cells have an 
important function in the initiation of immune responses, 
because they are specialized antigen-presenting cells whose 
primary functions are to capture, process, and present antigens to 
unprimed T cells (73). In the maturation process, dendritic 
cells originally develop from MHC class II-negative 
precursors, and then give rise to low MHC class II-positive 
cells (immature type). Finally, immature dendritic cells can 
further upregulate the expression of MHC class II molecules 
under stimulated conditions (73,74). 
Immunocytochemical detection of rat macrophage 
populations 
Detection of M0 populations in rat fibrosis models is essential to 
investigate their roles. As indicated above, M0 are a 
heterogeneous cell population (6,28,68,75). In the last 15 
years, useful monoclonal antibodies recognizing rat M0 have 
been generated. The characteristcs and reactivity of anti-rat 
M0 monoclonal antibodies, which have been widely used, 
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epitopes of antigens present on exudate M0 and certain M0 
populations in lymphoid organs. ED2 and Ki-M2R are reactive 
for resident M0 (28,68,70). EDI recognizes many M0 
populations, particularly, blood monocytes and exudate M0. 
However, since EDI-recognizing antigen is mainly on the 
membrane of cytoplasmic granules, particularly, phagolyso-
somes, of M0, the amount of EDI expression in a cell maybe 
dependent on phagocytic activity of these cells (76). Among 
these monoclonal antibodies, EDI and ED2 have been widely 
used to detect different M0 populations in experimental rat 
fibrosis(10,12-14,16,45,46,58,59,72,77,78). OX6is amonoclonal 
antibody against rat MHC class II antigen (la), and recognizes 
the mature dendritic cells by immunocyochemistry (58,59,72,78). 
MYOCARDIAL FIBROSIS 
Animal models for myocardial fibrosis 
Our laboratory has investigated the kinetics of MO and 
myofibroblasts in myocardial fibrosis induced in rats by 
isoproterenol, an p-adrenergic stimulant (16). The isoproterenol-
induced myocardial injury is characterized by multifocal necrotic 
lesions in the subendocardial portions of the left ventricle, 
followed by fibrous granulation and scar tissues. The 
pathological events in the model are similar to those seen in 
human myocardial infarctions and rat infarction models by 
coronary arterial ligation (1,59,79,80). Pcrivascular fibrosis in 
the left ventricle has also been reported in spontaneously 
hypertensive rats or reno vascular hypertensive rats induced by 
clipping renal artery (19,58,77,78). This fibrosis is caused by the 
decrease in left ventricular compliance and the increase in 
arrhythmogenic risk associated with cardiac overload (77,81). 
Transgenic mice expressing protein-tyrosine kinase were 
introduced as a myocardial fibrosis model (82). 
Myofibroblasts in myocardial fibrosis 
In rat myocardial infarction, myofibroblasts appeared between 
2 and 4 days (80). Similarly, on days 3-7 after isoproterenol 
injection, there was a dramatic increase in the number of myofib 
roblasts (16). In human myocardial fibrosis, myofibroblastic 
cells appear within 4 to 6 days after the infarction (50). The 
myofibroblasts produce ECM proteins, mainly collagen types 
I and III (1,83,84). Cardiac myofibroblasts can alter their 
cytoskeletal proteins. Willems et al (50) compared the chara 
cteristics of myofibroblasts in human myocardial fibrosis with 
those in rat cardiac infarction (85) and in rat dermal wounds (86). 
Myofibroblasts in all studies expressed both vimentin and a- 
SMA (VA cells). In contrast to dermal wounds that possess VA, 
DVD and VAD cells, desmin expression in cardiac myofibroblasts 
appears to be weak or lacking. The most interesting feature of 
myofibroblasts appearing in myocardial fibrosis is their parallel 
orientation to surviving adjacent cardiomyocytes (16,50,80). 
Myofibroblasts persist in fibrotic lesions in the myocardium for 
a long time, whereas they are only transiently present in dermal 
wounds (2,50,86). The persistence of myofibroblasts and their 
preferential alignment in myocardial fibrosis may be explained 
by the continuous mechanical stress caused by the ongoing 
contraction andrelaxation of the surrounding viable myocardium 
(16,50). The expression of the cytoskeletal a-SMA filaments 
provide the myocardial fibrotic cells with the possibility to 
contract and counteract the mechanical forces (reparative 
fibrosis) (50,85). Recently, cardiac myofibroblasts were shown 
to express a homologue of Drosophila tissue polarity gene 
frizzled (/z2) when migrating into the granulation tissues, and the 
expression is decreased after the cells have aligned. The/z2 may 
be involved in the spatial control of cardiac wound repair after 
infarction (87). However, the precise origin of cardiac myofib 
roblasts remains unclear. ^, 
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 This table is made by referring to reference 28. 
 
  
Antibody Isotype Site of recognition Reactive cell 
Membrane of cytoplasmic 
granules 
EDI Monocytes, most macrophages 
(particularly exudate macrophages) 
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Table 4. Characteristics of interstitial dendritic cells and resident macrophages in rat myocardium* 
Cell type 
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*This table is made by referring to reference 72.  
MACROPHAGE POPULATIONS IN NORMAL MYOCARDIUM 
M0 are normally present in the cardiac tissues. By using CD68 
pan M0 marker, the immunopositive cells are seen in the 
interstitium of normal human hearts, often close to blood 
vessels. The cardiac M0 are more frequently seen in the 
ventricles (88). However, CD68-positiveM0 were not identified. In 
rats, ED2-immunolabelled, resident M0 are observed in the 
interstitium of the myocardium; the numbers of ED2-positive 
cells per 0.1 mm2 in the normal myocardium was 6.3+7-2.5(16). 
The distribution of ED2-positive cells forms a regular network 
of the interstitial cells throughout the cardiac tissues. OX6-
immunopositive interstitial dendritic cells are also distributed 
diffusely in normal rat heart, their number being 8.2+7-1.0/0.1 
mm2 (59). Apparently, the distribution pattern of the interstitial 
dendritic cells is similar to that of the the resident M0. Spencer 
and Fabre (72) showed some differences between interstitial 
dendritic cells and resident M0 in rat hearts (Table 4). The 
interstitial dendritic cells constituti vely express large quantities of 
MHC class II antigens, and they are ED2-negative. In contrast, 
ED2-positive resident M0 do not reveal MHC class II antigens. 
Radiation administration experiments using l37Cs suggest that the 
turnover of the resident M0 is much slower than that of the 
interstitial dendritic cells. Besides these differences, the interstitial 
dendritic cells have no phagocytic activity (89). These studies 
indicate that the interstitial dendritic cells and resident M0 
represent two distinct populations in rat hearts. However, 
interferon gamma (IFN-y) induces MHC class II antigens on the 
resident M0 (72). Interstitial dendritic cells at immature stages, 
which are normally existing in connective tissues, do not exhibit 
MHC class II antigens at a high level (73). It was recently shown 
that dendritic cells have phagocytic activity, like resident and 
exudate M0 (90). The relationship between these cells still 
remains to be evaluated (Fig. 1). 
EXUDATE MACROPHAGES IN MYOCARDIAL FIBROSIS 
In isoproterenol-induced rat myocardial fibrosis, a markedly 
increased number of EDI-positive M0 was seen within the 
affected tissues immediately after the injection, reaching a 
peak on day 3 (16). Thereafter, the number decreased gradually, 
but remained abundant in the granulation tissues. ED 1 -positive 
cells appearing in injured tissues are usually regarded to be a 
result of migration into the injured site from circulating system 
(19,68). Marked infiltration of M0 have been reported in human 
myocardial infarction (91,92), but M0 populations related to the 
infarction and subsequent fibrosis have not been identified. 
The increased expression of LFA-1, Mac-1, VLA-4, and ICAM-1 
was detected on monocytes in human and rat myocardial 
infarctions (19,22,93). These molecules contribute to adhesion of 
monocytes to endothelia in the ischemic territory. The 
findings that LFA-1, Mac-1,1C AM-1, and VLA-4 were 
simultaneously expressed on monocytes indicate that 
monocytes can form microaggregates in the cardiac lesions (22). 
Estradiol treatment blunted the increased immunostaining of 
ICAM-1 in the injured rat myocardium, resulting in decrease 
in cardiac leukocyte accumulation (93). Expression of 
osteopontin on infiltrating M0 has been confirmed in rat and 
human myocardial necrotic lesions; it was increased in the 
early stages and dramatically downregulated as healing 
proceeds (17). These findings indicate that several adhesion 
molecules take part in both extravasation of monocytes and 
cellular adhesion of exudate M0 in myocardial fibrosis. In 
cardiac lesions, plasma renin activity and blood pressure affect 
M0 density through stimulating CAM (78). 
Relationship between exudate macrophages and myofib-
rob lasts 
Figure 2 shows the kinetics of M0 populations and myo-
fibroblasts in rat myocardial fibrosis. Exudate M0 play an 
important role in development of fibrosis by producing various 
cell growth factors (7-9,33). In isoproterenol-induced rat 
myocardial fibrosis, after the maximal emergence of ED1-
positive M0, the myofibroblast number was significantly 
increased on days 3-7 when fibrous granulation tissues began to 
be formed (16). In spontaneously/renovasucular hypertensive 
rats, many EDI-positive M0 were seen in perivascular 
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date M0 influx from the blood in response to tissue injury is 
important in mediating myofibroblast induction and 
proliferation through products released by the M0. In 
chemically-and cholestatic-induced rat liver fibrosis, the 
number of my-ofibroblastic perisinusoidal cells markedly 
increased following an expansion of EDl-positive M0 
(10,45). Intriguingly, the expression of leptin, an obese (pb) 
gene product, was reported in hepatic stellate cells and 
circulating leptin level elevated in patients with alcoholic 
cirrhosis (94), suggesting a link between the cell biology of 
fibrosis and adipose tissue (94,94a). In cisplatin-induced rat 
renal interstitial fibrosis, EDl-positive M0 influx was related 
to myofibroblast involvement in the early stages (12,13). 
Essential fatty acid-deficient diet or protein-restricted diet 
inhibits M0 infiltration, and the administration of such a diet 
to rats results in a reduction of interstitial fibrosis in 
puromycin aminonucleo-side-induced nephrosis (60,95). The 
administration of suble-thal X irradiation to ureteral obstructed 
rats also resulted in a decrease in both macrophage number 
and development of myofibroblasts in early stages of the 
fibrosis (7). There is a close relationship between M0 influx 
and myofibroblast involvement in fibrogenic lesions. 
Fibrogenic cell growth factors and exudate M0 and PDGF 
produced by M0 are the most often implicated factors for the 
induction of myofibroblast development in fibrogenic lesions. 
In hepatic and renal fibrosis, increased expression of 
mRNATGF~|M has been well documented, and expression of 
TGF-p was found on macro-phages by immunostaining or 
hybridization methods (7,29,34,38,60,95). 
TGF-J31 is present in the developing and adult heart (96,97). 
Its immunoreactivity disappeared in the central necrotic part of 
rat myocardial infarctions, but a strong immunoreactivity and 
increased mRNA amounts were found mostly in myocytes at 
the margins of the infarcted areas (98). Increased production of 
collagen types I and III at the mRNA and protein levels was 
confirmed in rat infarcted myocardium, and the source in the 
myocardial fibrosis was myofibroblasts (1,84). Collagen 
production by cardiac fibroblasts was stimulated by TGF-pl 
(99-101). Moreover, cultured cardiac fibroblasts were shown to 
secrete TGF-J31 which can be stimulated by angiotensin II, 
suggesting that myofibroblastic cells in myocardial fibrosis act as 
an autocrine/paracrine stimulus to collagen formation (102). 
These observations strongly indicate thatTGF-(3l is important 
for development of myocardial fibrosis. Besides cardiomyocytes 
and myofibroblasts, exudate M0 can produce TGF-[3 
demonstrated in hepatic, renal and pulmonary fibrosis 
(5,7,29). However, there has been no direct demonstration of 
TGF-P production of exudate M0 in myocardial fibrosis (19). 
The exogenous administration of PDGF-BB to rats induces 
development of myofibroblasts and accumulation of collagen 
type III within the kidney interstitium (37). In renal interstitial 
fibrosis and glomerulosclerosis, a possible origin of PDGF is 
infiltrating M0 and platelets as well as regenerating renal 
tubular epithelia (4,8,15). Increased expression of mRNAPDGF~ AA 
was reported in the heart of renovascular hypertensive rats (19). 
PDGF-AA is a potent mitogen for cardiac fibroblasts 
(103), and stimulates collagen production by cardiac 
fibroblasts (101). However, the contribution of PDGF-AA 
and -BB to myocardial fibrosis remains uncertain (19). 
TNF-cc is thought to act as an early trigger for the fibrotic 
cascade (25,104). However, unlike TGF-(3 and PDGF that serve as 
direct growth factors mediating myofibroblast development and 
ECM production, TNF-a has weak or negative effects on 
fibroblast proliferation and matrix production, and, by itself, is 
unable to induce the myofibroblastic phenotype in vitro or in 
vivo (25,105). Cardiac M0 were reported to produce TNF-a 
(104), but its association with myocardial fibrosis has not yet 
been investigated. Rather, M0-produced TNF-a contributes to 
myocardial dysfunction and cardiomyocyte death (apoptosis) in 
ischemic and chronic heart failure and cardiac allograft 
rejection (104). Note that mast cell chymase induces both 
cardiomyocyte apoptosis and myocardial fibroblast 
proliferation, thus contributing to the progression of heart 
failure (106). GM-CSF and bFGF have been reported to induce 
fibrotic responses with accumulation of myofibroblasts 
(24,35,108,109). The mechanisms underlying GM-CSF- or 
bFGF-related myofibroblast phenotypes await clarification. 
GM-CSF and bFGF production by macrophages has not yet 
been studied in myocardial fibrosis. In short, although cell 
growth factors such as TGF-J3, PDGF, TNF-a, GM-CSF, bFGF, 
and NGF have been suggested to be important in the induction of 
fibrogenic cells and ECM production (106,107) and the M0 
infiltrating the fibrosing lesions are seen as possible source of 
such growth factors, the contribution of s"uch growth factors to 
myocardial fibrosis has not sufficiently been evaluated. 
RESIDENT MACROPHAGES AND INTERSTITIAL 
DENDRITIC CELLS IN MYOCARDIAL FIBROSIS 
ED2-positive resident M0 also participate in the development of 
rat myocardial fibrosis (16,58,59). In isoproterenol-induced rat 
myocardial fibrosis, however, the peak of ED2-positive cell 
number was different from that of EDl-positive M0, in that 
ED2-positive cell number was maximal on day 14 in the late 
stages (16) (Fig. 2). TheED2-positive cells showed proliferative 
activity, demonstrable by the double-labelling methods with 
bromo-deoxyuridine antibody (16). An increased number of 
OX6-positive interstitial dendritic cells was maximal at the 
border zones between normal and necrotic areas 7-14 days after 
coronary ligation (59). The time of appearance and the 
distribution of resident M0 correspond to those of the 
interstitial dendritic cells (16) (Fig. 2). It thus is considered that 
in the fibrotic lesions the roles of resident M0 are similar in 
part to those of the interstitial dendritic cells. The roles of 
resident M0 in myocardial fibrosis are poorly understood. 
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studies on resident M0 in other organs or on the interstitial 
dendritic cells in the myocardium. 
Kupffer cells in hepatic fibrosis and granulomas 
Kupffer cells are a well known resident M0 (6). In CCl4-induced 
rat hepatic fibrosis, ED2-positive Kupffer cells are markedly 
increased in injured areas following the expansion of ED1-
positiveM0;proliferative activity of Kupffer cells was confirmed 
(10,45). After the increased in the number of EDI- and ED2-
positive M0, myofibroblastic perisinusoidal cells increased in 
the affected areas. mRNATGF~pl levels also increased dramatically 
following CCl4-induced hepatic injury (29). Themostimportant 
profibrogenic factor in hepatic fibrosis is TGF-(31, produced by 
ED 1 - and ED2-positi ve M0 (5,29). Gadolinium chloride blocks 
phagocytosis by Kupffer cells and selectively eliminates 
activated Kupffer cells (69,110). The treatment with gadolinium 
chloride reduced liver injury and subsequent fibrosis in rats 
receivingchronicethanoladministrationorCCl4treatment(l 11). 
Infiltrating M0 and Kupffer cells also take a part in the formation 
of hepatic granulomas. Liposome-encapsulated dichloro-
methylene diphosphonate given intravenously is ingested by 
M0 and kills them by inducing apoptosis (112). Using this 
model, it was recently reported that the number and size of the 
granulomas induced by zymosan were reduced in the Kupffer 
cell-depleted mice, compared with those of untreated mice (27). 
The finding that M-CSM and its receptor c-fms in M0 are 
involved in zymosan-induced granuloma formation is similar to 
that seen with glucan-induced granuloma formation in the 
Kupffer cell-deficient M-CSF null mutant op/op mice (26). The 
preexisting Kupffer cells form a microen vironment important for 
M0-related granuloma formation accompanied with 




Figure 2. The kinetics of macrophage populations and my ofibroblasts in experimental rat myocardialfibrosis. In the early 
stages of the fibrosis, the exudate macrophages which are derived from blood monocytes quickely increase. They can induce the 
development of myofibroblasts by producing cell growth factors such as TGF-fi and PDGF. The resident macrophages 
gradually increase by dividing and participate in the advance of myocardial fibrosis by releasing cell growth factors similar to 
those released by the exudate macrophages. The interstitial dendritic cells have a similar appearance and distribution 
patterns to the resident macrophages. The resident macrophages and interstitial dendritc cells are important in immune-
mediated T cell induction in the advanced stages of the myocardialfibrosis. Thefibrosing tissues consist of my ofibroblasts and 
extracellular matrix proteins such as collagen types I and III. The myofibroblasts contribute to the reparative fibrosis in the 
myocardium. As the scar tissues develop, the cell components in thefibrosing tissues are decreased by apoptosis, which may be 
mediated by tnacrophage-produced factors such as TNF-CL and NO. Apoptotic cells are phagocytized by the exudate and 
resident macrophages. The major events in phases 1-3 of the fibrogenesis are shown in Table 2. 
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to secrete a number of growth factors including TGF-fS and 
CSF (5,6,27). In hepatic fibrosis and granulomas, Kupffer 
cells contribute, as do exudate M0, to the production of cell 
growth factors capable of inducing myofibroblastic cell 
development. 
Interstitial resident macrophages in pulmonary fibrosis 
In rat lungs, alveolar M0 are positive for ED 1, but not for ED2 
(68). The alveolar M0 are probably derived from blood 
monocytes(l 13). Onthecontrary,mostinterstitialM0areED2-
positiveresidentM0(68). In the generation of mouse pulmonary 
fibrosis after silica injection, it was found that the interaction 
between particles and M0 within the interstitium is more important 
than that occurring in the alveolar space in stimulating the 
fibrotic process (114). The close contact between M0 and 
fibroblasts within the interstitium may permit a more efficient 
transfer of M0-derived growth factors to preexisting fibroblasts. 
Interstitial macrophages secrete various cell growth factors 
including bFGF, TGF-(3 andTNF-a. Such growth factors have 
been demonstrated to be involved in development of various 
types of pulmonary fibrosis (24,40,105,114). 
Resident macrophages in renal interstitial fibrosis 
In experimental tubulointerstitial fibrosis in rats, ED 1 -positive 
exudate M0 contribute to the induction of myofibroblasts (12-
14,51,60,95). In contrast, ED2-positive M0 were not detected in 
the affected areas in the renal fibrosis, although such cells are 
present in the vicinity of the arcuate and interlobular arteritis 
(12,14). It thus appears that the resident M0 do not participate in 
rat renal fibrosis. However, tissue M0 exist in the normal 
kidneys. Locally-produced factors may inhibit the maturation of 
these cells and their participation in the formation of fibrotic 
lesions in the kidneys (72). 
Interstitial dendritic cells in myocardial fibrosis 
Appearance of OX6-positive interstitial dendritic cells has been 
reported in rat myocardial fibrosis (19,58). The dendritic cells are 
probably mobilized from bone marrow in response to tissue 
injury (Fig. 1), and the interstitial dendritic cells differentiate 
under the influence of locally produced growth factors such as 
GM-CSF,TNF-oc, andinterleukin(IL)-l|3(58,59,73). Activated 
interstitial dendritic cells up-regulate MHC class II molecules, 
and the interstitial dendritic cells are major antigen-presenting 
cells (73). They have several mechanims for antigen interna-
lization. The best characterized pathways are phagocytosis and 
pinocytosis, in addition to mannose receptor-mediated 
endocytosis (74,90,115). It is thought that, after myocardial 
necrosis, the interstitial dendritic cells present heart-derived 
antigenic components to helper T-lymphocytes. Indeed, the 
appearance of CD4-positive helper T-lymphocytes in rat hearts 
after infarction was shown to be associated with the formation of 
clusters consisting of interstitial dendritic cells (57-59). T cells 
primed by the interstitial dendritic cells produce IL-1 ,-2, and 
cytokines involved in Thl/Th2 lymphocyte polarization are 
produced locally by the interstitial dendritic cells (59,73,116). 
Roles of resident macrophages in myocardial fibrosis 
Resident M0 reside in connective tissues throughout the body 
are stimulated to proliferate after the onset of injury (65,68,72) 
(Fig. 1). In fibrotic lesions, like exudate M0, the resident M0 
show phagocytic activity, and produce a variety of cell growth 
factors including TGF-p, PDGF, TNF-oc, bFGF, and CSF which 
can induce myofibroblast activation directly or indirectly. In 
addition, the resident M0 may play an important role in the 
presentation of highly immunogenic antigen to the T-lymphocyte 
system as antigen-presenting cells, like the interstitial dendritic 
cells. However, the repertoire of growth factors secreted by the 
resident M0, which can contribute to the development of 
myocardial fibrosis and the regulation of the healing process, 
remains to be clarified. Yet, a question remains as to whether an 
increase in M0 number is causally related to or associated with 
the development of fibrosis (see 117 for mast cells in fibrosis 
induced in Ws/Ws mast cell-deficient rats). 
Anitschkow myocytes in myocardial fibrosis 
Anitschkow myocytes, which have been observed frequently at 
the border of the healing infarct (79) and in tissues of cardiac 
tumors (118), are characterized by caterpillar-like configuration of 
nuclear chromatin. The possible origin of these cells is still 
unknown, but myocytes, nerves, histiocytes, endothelial cells 
and fibroblasts have been proposed as possible precursors (79). In 
rat myocardial fibrosis, such cells are ED2 positive. This indicates 
that Anitschkow myocytes are resident M0-derived cells. Similar 
cells are also seen in rheumatic fever in humans and animals 
in association with Aschoff bodies. The functional roles of 
such cell types remain to be evaluated. 
APOPTOSIS AND MACROPHAGES IN MYOCARDIAL FIBROSIS 
Apoptosis is amechanism of programmed cell death that occurs 
in a range of physiological processes such as embryonic 
differentiation and development (reviewed in 119). In the last 
few years, it has been shown that apoptosis plays a major role in 
promoting resolution of inflammatory responses (2,9). 
Apoptosis is also the mechanism for the evolution of granulation 
tissues into scar tissues with a striking decrease in cellularity (2). 
In skin wound healing, many myofibroblasts showed changes 
compatible with apoptosis (2). Polunovsky et al (120) have 
reported a role for mesenchymal cell death in lung remodeling 
after acute injury. In hepatic fibrosis, myofibroblastic peri-
sinusoidal cells underwent apoptosis during the repair (3). We 
investigated the appearance of apoptotic cells in isoproterenol-
induced myocardial fibrosis by the terminal 
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end labeling method; only a few myofibroblasts showing DNA 
fragmentation were found (unpublished data). The number of 
apoptotic cells was much smaller than that we expected, given 
the active apoptosis of myofibroblasts that occurs in rat 
tubulointerstitial fibrosis induced by PDGF-BB injection 
(37). Generally, it is thought that apoptotic processes are an 
extremely rapid means of cell deletion; the development of 
morphological changes, uptake by phagocytosis, and 
degradation of the ingested apoptotic cells beyond histological 
recognition are completed in 30 minutes to 3 hours (37,121). 
The lower number of detectable apoptotic cells may be due to 
these rapid processes. In myocardial fibrosis, apoptosis in 
myofibroblasts and affected myocytes may be one biological 
process involved in tissue remodeling after myocyte injury. 
Several proteins or antigens have been known to regulate 
apoptosis. Among them Fas antigen, p53, and c-myc protein 
stimulte apoptosis, whereas bcl-2 protein inhibits apoptosis 
(3,122,123). C-myc and interleukin-1 p-converting enzyme have 
been shown to induce apoptosis in fibroblasts (124,125), and 
fibroblasts lack bcl-2 expression as assessed by the antibody 
staining (126). These situations may be involved in apoptosis in 
myofibroblasts, because myofibroblasts are considered 
terminally differentiated fibroblasts (2,47). Cytokines such as 
TNF-oc and TGF-P have been shown to induce apoptosis in 
hepatocytes in vitro and in vivo (119,127). These cytokines are 
present in the fibrotic tissues, suggesting that apoptosis in the 
fibrotic lesions is cy tokine-dependent (2,128). The main sources of 
these factors are exudate and activated resident M0. The 
increased activity of inducible nitric oxide synthase (iNOS), 
which catalyzes the reaction of L-arginine to L-citrulline and 
nitric oxide (NO), is also related to the induction of apoptosis in 
myocytes in myocardial infarction and allograft rejection 
(129,130). The immunohistochemical localization revealedM0 as 
amajorsourceof iNOS expression (129-131). In inflammatory sites, 
clearance is accomplished mostly by M0 engulfment of cells 
undergoing apoptosis (2,9,63). The strongest candidate for the 
M0 receptors responsible for recognition of apoptotic cells is 
the phosphatidylserine receptors (PSR), which has yet to be 
characterized, although candidates for PSR function include 
several types of scavengerreceptors (9). In inflammatory resolution, 
M0 engulfing cell debris appear to leave the inflamed site via 
lymphatics, and die by apoptosis in adjacent lymph nodes 
(132). Recently, it was reported in experimentally-induced rat 
crescent!c glomerulonephritis that M0 themselves undergo 
apoptosis at inflamed sites (64). Apoptotic M0 have been 
found at border zones adjacent to the infarcted myocytes in 
rabbit models (131,133) and in isoproterenol-induced rat 
myocardial fibrosis (unpublished data). Terminally differentiated 
dendritic cells appear to die locally by apoptosis (73). Myo-
fibroblast and myocyte apoptosis, mediated by M0-produced 
factors, the subsequent uptake by M0 and the apoptosis of the M0 
themselves are the major method of inflammatory clearance and 
subsequent tissue remodeling in myocardial fibrosis. 
THERAPEUTIC IMPLICATIONS: CONTROL OF 
MACROPHAGES AND MACROPHAGE-PRODUCED FACTORS 
For the normal healing of fibrosis, the availability of the 
signaling substances must be optimal, precise, and 
synchronized. Inhibition, interruption or excess expression of 
these signals seems to be responsible for failure in healing, 
which is manifested by either impairment (nonhealing) or 
excess tissue formation (134). M0 and their secretory products 
play an important role in the fibrogenesis and resolution. The 
regulation and removal of M0 and/or M0-secreted growth 
factors/ cytokines are avenues of therapeutic potential for 
fibrotic lesions, including myocardial fibrosis. Indeed, 
treatments designed to inhibit M0 infiltration could reduce 
the degree of fibrotic lesions in experimental fibrosis models of 
the liver and kidneys (see above Sections: "Relationship 
between exudate macrophages and myofibroblasts" and 
"Kupffer cells in hepatic fibrosis and granulomas"). 
Furthermore, accumulating findings demonstrate that micro-
tubule-disassembling (antitubulin) agents, particularly, col-
chicine, may inhibit (;') the release of certain proinflammatory/ 
fibrogenic cytokines (135) and MMP (136), and (ii) the intracellular 
secretory pathway in various fibrogenic cells (reviewed in 
137). It is noteworthy that colchicine and other antitubulins 
upregulate the expression of mRNANGF in neuronal cells and also 
in skin fibroblasts (13 8). And NGF treatment may improve the 
healing process in various tissues (107,139-141). 
Another therapeutic approach may include the antibodies 
neutralizing cell growth factors, as demonstrated in experimental 
fibrosis models. For example, antibodies to TGF- P reduce hepatic 
and pulmonary fibrosis, and glomerulosclerosis (29,142), 
whereas TNF-a antibodies ameliorate pulmonary fibrosis 
(32,143). Alpha 2-macroglobulin (oc2M) is aprotein thatregulates 
the distribution and activity of many growth factors such as 
TGF- p, TNF-a, and PDGF, and hence may also be a therapeutic 
target for fibrosis (reviewed in 144). Strategies to interfere with 
TGF-p activity, such as through the administration of decorin 
(leucine-rich proteoglycan), have been successful in limiting 
disease in experimental fibrotic models (145). Recently, the 
usage of antisense oligonucelotides against cell growth factors 
has been reported in growth factor-mediated disease states. For 
example, the administration of antisense oligonucleotides to 
TGF-p 1 effectively blocked M0 expression of TGF-P 1, resulting in 
the prevention of progressive fibrosis (134). Adenosine, 
which reduces TNF-a production by M0, decreases cardiac 
TNF-a level and improves postischemic myocardial function 
(107). M0 are a major source of iNOS production, which is 
related to the induction of apoptosis in cardiomyocytes. The 
preferential inhibition of iNOS by S-methylisothiourea sulfate 
resulted in a significant improvement of left ventricular 
performance and increased regional myocardial blood flow in 
rabbit cardiac infarction models (129). The selective inhibition of 
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in cardiovascular fibrosis. However, the efficacy and safety of 
these therapeutic strategies for regulating M0 and M0-pro-
duced soluble factors have not yet been established in human 
myocardial fibrosis. 
CONCLUSION 
M0 are heterogeneous cell populations and show various roles in 
the fibrotic lesions. In myocardial fibrosis, exduate and 
resident M0 and interstitial dendritic cells are involved. In the 
early stages, exudate M0 derived from blood monocytes play a 
major role in induction of myofibroblasts to develop fibrous 
granulation tissues by producing cell growth factors such as 
TGF-P, PDGF, TNF-a, bFGF, NGF, and CSF. Thereafter, the 
resident MO gradually increase by dividing and participate in 
the advance of myocardial fibrosis by releasing cell growth 
factors similar to those released by exudate M0. Although the 
relationship between residentM0 and interstitial dendritic cells 
has to be further investigated, these cells appear to be important in 
immune-mediated T cell induction in the advanced stages of 
myocardial fibrosis. The repair of myocardial cell death terminates 
with the establishment of scar tissue consisting of 
myofibroblasts, small vessels and ECM components such as 
collagen types I and III (reparative fibrosis). As the scar evolves, 
the cell components are decreased by apoptosis, which may be 
mediated by M0-secreted factors such as TNF-a and iNOS. 
Apoptotic cells arc phagocytized by the exudate and resident 
M0. The regulation of M0 and M0-produced factors may 
provide novel therapeutic strategies in clinical trials of 
myocardial fibrosis. 
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